Population model successfully developed to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad range of ...

Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical ...

The Crime Branch of Delhi Police has busted a racket selling spurious cancer medicines and injections, arresting six ...

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing ...

The accused individuals were selling spurious cancer medicines and injections, including Opdivo, Pembrolizumab Injection, Keytruda, and others, without proper authorisation. The police raided three ...

Chinese doctors have reported a milestone in domestically made innovative medicine, announcing that a combination of ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports.

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced it has secured exclusive ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Updated data on IBI363 monotherapy in patients with advanced NSCLC were reported (ClinicalTrials.gov, NCT05460767). As of the ...

The meeting of the American Society of Oncology focused on optimizing immunotherapy and other advanced treatments for ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...